For the last several years, GLP-1 drugs have reshaped the weight-loss, telehealth, med spa, and direct-to-consumer healthcare markets. Semaglutide, tirzepatide, liraglutide, and related drugs created enormous patient demand. Drug shortages created room for compounding. Telehealth companies made access faster. Med spas and wellness clinics built new service lines. Pharmacies found themselves in the middle of one of the most commercially important healthcare trends in the country.
That phase is now changing.
The GLP-1 market is no longer just a story about demand, access, and affordability. It is becoming a story about FDA enforcement, compounding limits, marketing claims, product sourcing, patient-specific documentation, and litigation by brand manufacturers.
In plain English: the GLP-1 gold rush is entering its enforcement phase.
What Changed?
The biggest mistake companies can make right now is assuming that GLP-1 compliance is still only about whether a drug is "in shortage." That was never the whole analysis, and it is now clearly inadequate.
FDA's recent actions show a broader enforcement theory. FDA is focused on whether compounded GLP-1 products are being marketed as if they are FDA-approved drugs, whether companies are implying that compounded products are generic or equivalent to branded drugs, whether compounded formulations are truly patient-specific, whether additives are being used as a legal workaround, and whether the supply chain can support the quality and safety representations being made to patients.
FDA's Office of Compliance reported that, in 2025, it issued 58 warning letters to telehealth companies selling misbranded compounded products where advertising or promotion allegedly implied that unapproved compounded products had been FDA-approved or obscured important differences between compounded drugs and FDA-approved medications.
The First Tranche: Misleading Advertising Became the Target
In September 2025, FDA announced a broader crackdown on deceptive direct-to-consumer pharmaceutical advertising. FDA stated that it was sending thousands of letters warning pharmaceutical companies to remove misleading ads and issuing approximately 100 cease-and-desist letters to companies with deceptive ads. FDA also emphasized that digital and social media advertising, including influencer promotion, had blurred the line between evidence-based information and promotional material.
That matters for GLP-1 companies because many of these business models are marketing-driven. The patient often does not start with a local physician or pharmacy. The patient starts with a Google search, TikTok video, Instagram ad, landing page, online quiz, or subscription checkout flow.
FDA's position is not subtle. Compounded drugs are not FDA-approved, and compounded drugs are not the same as FDA-approved generics. FDA has expressly identified claims implying sameness with FDA-approved products as a primary violation in its GLP-1 warning letters.
This is why phrases like "generic Ozempic," "generic Wegovy," "same as Mounjaro," "same active ingredient," "clinically proven," or "FDA-approved ingredient" are legally dangerous when used to sell or promote compounded GLP-1 products.
The Second Tranche: FDA Expanded From Marketing to Product Integrity and Safety
FDA's published concerns regarding unapproved GLP-1 drugs used for weight loss extend beyond website copy. FDA identified concerns involving improper storage during shipping, questionable imported GLP-1 APIs, fraudulent compounded products, dosing errors, adverse events, semaglutide salt forms, and products falsely labeled "for research purposes" or "not for human consumption."
That update is important because it moves the issue from "Did the website say something too aggressive?" to "Can the company actually defend the product, the supply chain, the dosing, the pharmacy relationship, and the patient instructions?"
FDA also stated that retatrutide and cagrilintide cannot be used in compounding under federal law and that semaglutide sodium and semaglutide acetate are different active ingredients than those used in approved drugs, with FDA stating it was not aware of any lawful basis for their use in compounding.
For med spas, telehealth companies, MSOs, and pharmacies, that should be a major warning. GLP-1 compliance is not just a marketing review. It is vendor diligence, pharmacy diligence, API diligence, label review, shipping review, adverse event procedures, prescription documentation, and patient education.
The Third Tranche: Telehealth Branding Became a Specific Enforcement Issue
On March 3, 2026, FDA announced 30 warning letters to telehealth companies for allegedly making false or misleading claims regarding compounded GLP-1 products offered on their websites. FDA described this as the second group of warning letters sent to telehealth firms since the September 2025 advertising crackdown.
FDA identified two particularly important categories of violations: claims implying sameness with FDA-approved products, and product sourcing claims that allegedly obscured who actually compounded the drug. In its February 20, 2026 MEDVi warning letter, FDA objected to compounded semaglutide and tirzepatide products displayed with the telehealth company's name on the pictured label, suggesting that the telehealth company was the compounder when FDA said it was not. FDA also objected to claims such as "Same active ingredient as Wegovy® and Ozempic®" and "Same active ingredient as Mounjaro® and Zepbound®."
That is a very practical warning. Many GLP-1 companies try to build a clean consumer brand around a product they do not manufacture, compound, dispense, or clinically control. That branding strategy may help conversion rates, but it can also create regulatory risk if the patient is misled about who is providing medical services, who is compounding the drug, whether the product is FDA-approved, or how the product compares to branded drugs.
The Legal Issue Is Not "Compounding Is Illegal"
The stronger and more accurate point is this: the defensible pathway has narrowed.
Compounding is not automatically unlawful. Federal law expressly recognizes pharmacy compounding and outsourcing facilities. But those pathways have conditions. The statutory text matters.
For traditional 503A compounding, the statute says the compounder must not compound "regularly or in inordinate amounts" drug products that are "essentially copies" of commercially available drug products. FDA’s section 503A guidance explains this limitation and the patient-specific significant-difference analysis.
For 503B outsourcing facilities, the statute says the facility may not compound using bulk drug substances unless the substance appears on FDA's clinical-need list or the compounded drug appears on FDA's shortage list at the time of compounding, distribution, and dispensing. FDA’s April 2026 clarification discusses these conditions and the then-current status of semaglutide and tirzepatide.
That is the legal center of the current fight. The question is not whether patients want less expensive GLP-1 access. Of course they do. The question is whether a particular compounded GLP-1 program fits within the limited legal pathways that Congress and FDA recognize.
FDA's April 2026 Clarification Addressed the "Additive Strategy"
For many GLP-1 programs, the theory has been some version of this: add vitamin B12, glycine, niacinamide, pyridoxine, or another ingredient, then argue the drug is no longer a copy.
FDA's April 1, 2026 clarification makes that strategy much harder to rely on as a general business model.
FDA stated that, under section 503A, a compounded drug product may be treated as essentially a copy if it has the same API as the commercially available drug product in the same, similar, or easily substitutable strength and can be used by the same route of administration, unless the prescriber determines and documents a significant difference for the identified individual patient. FDA also addressed combination products, stating that a compounded product combining semaglutide API with another API, such as vitamin B12, may still be considered essentially a copy when the drug products use the same route and the strengths are within 10% of the respective commercially available drug products.
That does not mean every compounded GLP-1 formulation is unlawful. It does mean that the analysis needs to be patient-specific, clinically real, and documented. A mass-market formulation change designed primarily to preserve a business model is not the same thing as a prescriber determining that an identified patient needs a specific compounded formulation because the commercially available drug does not meet that patient's medical needs.
That distinction is now where much of the legal risk sits.
What Should GLP-1 Companies Review Now?
The enforcement landscape has shifted enough that companies operating in the GLP-1 space should consider a structured compliance review. That review should address marketing claims and website language, the compounding pharmacy relationship and its regulatory status, patient-specific documentation and prescriber workflows, product sourcing and API provenance, labeling and packaging, informed consent and patient education materials, and adverse event reporting procedures.
The right answer depends on how the business is structured, which states it operates in, which pharmacy it works with, and what claims it is making. There is no single GLP-1 compliance checklist that works for every business model.
But the general direction is clear: companies that built GLP-1 programs on broad consumer demand, shortage-based compounding, and competitive pricing are now operating in a more constrained legal environment. The time to assess that is before a warning letter arrives, not after.